Targeting GIRK Channels for the Development of New Therapeutic Agents by Kenneth B. Walsh
ORIGINAL RESEARCH ARTICLE
published: 31 October 2011
doi: 10.3389/fphar.2011.00064
Targeting GIRK channels for the development of new
therapeutic agents
Kenneth B.Walsh*
Department of Pharmacology, Physiology and Neuroscience, School of Medicine, University of South Carolina, Columbia, SC, USA
Edited by:
Ralf Franz Kettenhofen, Axiogenesis
AG, Germany
Reviewed by:
Maurizio Taglialatela, University of
Molise, Italy
Owen McManus, Johns Hopkins
University, USA
Gregory John Kaczorowski, Kanalis
Consulting, L.L.C., USA
*Correspondence:
Kenneth B.Walsh, Department of
Pharmacology, Physiology and
Neuroscience, School of Medicine,
University of South Carolina,
Columbia, SC 29208, USA.
e-mail: walsh@uscmed.sc.edu
G protein-coupled inward rectiﬁer K+ (GIRK) channels represent novel targets for the devel-
opment of new therapeutic agents. GIRK channels are activated by a large number of G
protein-coupled receptors (GPCRs) and regulate the electrical activity of neurons, cardiac
myocytes, and β-pancreatic cells. Abnormalities in GIRK channel function have been impli-
cated in the patho-physiology of neuropathic pain, drug addiction, cardiac arrhythmias, and
other disorders. However, the pharmacology of these channels remains largely unexplored.
In this paper we describe the development of a screening assay for identifying new modu-
lators of neuronal and cardiac GIRK channels. Pituitary (AtT20) and cardiac (HL-1) cell lines
expressing GIRK channels were cultured in 96-well plates, loaded with oxonol membrane
potential-sensitive dyes and measured using a ﬂuorescent imaging plate reader. Activation
of the endogenous GPCRs in the cells caused a rapid, time-dependent decrease in the ﬂuo-
rescent signal; indicative of K+ efﬂux through the GIRK channels (GPCR stimulation versus
control, Z ′-factor= 0.5–0.7). As expected this signal was inhibited by addition of Ba2+ and
the GIRK channel toxin tertiapin-Q.To test the utility of the assay for screening GIRK chan-
nel blockers, cells were incubated for 5min with a compound library of Na+ and K+ channel
modulators. Ion transporter inhibitors such as 5-(N,N -hexamethylene)-amiloride and SCH-
28080 were identiﬁed as blockers of the GIRK channel at sub-micromolar concentrations.
Thus, the screening assay will be useful for expanding the limited pharmacology of the
GIRK channel and in developing new agents for the treatment of GIRK channelopathies.
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INTRODUCTION
G protein-coupled inward rectiﬁer K+ (GIRK) channels function
as cellular mediators of a wide range of hormones and neuro-
transmitters and are expressed in the brain, heart, skeletal muscle,
and endocrine tissue (Hibino et al., 2010; Lusscher and Slesinger,
2010). GIRK channels aremembers of the super-family of proteins
known as inward rectiﬁer K+ (Kir) channels (Hibino et al., 2010;
Lusscher and Slesinger, 2010) that function to stabilize the cell rest-
ing membrane potential near the K+ equilibrium potential (EK).
Four GIRK channel subunits are expressed in mammals: GIRK1
(Kir3.1), GIRK2 (Kir3.2), GIRK3 (Kir3.3), and GIRK4 (Kir3.4;
Hibino et al., 2010; Lusscher and Slesinger, 2010). The GIRK1,
GIRK2, and GIRK3 subunits are expressed in a number of regions
of the brain including the hippocampus, cerebellum, substan-
tia nigra, locus coeruleus, and ventral tegmental area (Lusscher
and Slesinger, 2010). In addition, GIRK1 and GIRK2 subunits
are expressed in the superﬁcial layers of the spinal dorsal horn
and are enriched in the postsynaptic membranes of substantia
gelatinosa neurons (Lusscher and Slesinger, 2010). In neuronal
tissue GIRK subunits combine to form both heterotetrameric
(e.g., GIRK1/GIRK2, GIRK1/GIRK3, etc.) and homotetrameric
(GIRK2/GIRK2) channels. In the atrial myocardium and sinus
and atrioventricular nodes of the heart, GIRK channels are com-
posed of heteromers of GIRK1 and GIRK4 subunits (Hibino et al.,
2010).
G protein-coupled inward rectiﬁer K+ channels become acti-
vated following the binding of ligands to their cognate G
protein-coupled receptors (GPCRs). This binding causes the dis-
sociation of the βγ subunits of pertussis toxin-sensitive G proteins
which subsequently bind to and activate the GIRK channel. Once
opened the GIRK channel allows the movement of K+ out of
the cell causing the resting membrane potential to become more
negative. As a consequence, GIRK channel activation in neurons
decreases spontaneous action potential formation and inhibits the
release of excitatory neurotransmitters. In the heart, activation of
the GIRK channel inhibits pacemaker activity thereby slowing the
heart rate.
G protein-coupled inward rectiﬁerK+ channels represent novel
targets for the development of new therapeutic agents for the
treatment neuropathic pain, drug addiction, cardiac arrhythmias,
and other disorders. However, the pharmacology of these chan-
nels remains largely unexplored. Although a number of drugs
including anti-arrhythmic agents, antipsychotic drugs, and anti-
depressants block the GIRK channel (Kobayashi and Ikeda, 2006),
this inhibition is non-selective and occurs at relatively high drug
concentrations. In this paper we describe the development of a
screening assay for identifying new modulators of neuronal and
cardiac GIRK channels. Pituitary (AtT20) and cardiac (HL-1)
cell lines expressing GIRK channels were analyzed using patch
clamp recording procedures and ﬂuorescent imaging plate reader
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measurements. Application of the GPCR ligands somatostatin
(AtT20 cells) and carbachol (HL-1 cells) activated whole-cell
GIRK currents that were blocked by the Kir channel selective
toxin tertiapin-Q. In cells loaded with the membrane potential-
sensitive ﬂuorescent dye HLB 021-152, GPCR stimulation caused
a rapid, time-dependent decrease in the ﬂuorescent signal. This
GPCR-induced decrease in ﬂuorescence was block by BaCl2 and
tertiapin-Q. A preliminary screen of the GIRK channel ﬂuores-
cent assay identiﬁed several ion transporter inhibitors as blockers
of the channel. Thus, theGIRK channel screening assaywill be use-
ful for expanding the limited pharmacology of the channel and for
developing new agents for the treatment of GIRK channelopathies.
MATERIALS AND METHODS
CELL CULTURE AND PLATING
The immortalized cardiac HL-1 cell line was generously sup-
plied by Dr. William Claycomb (LSU Medical Center, New
Orleans, LA, USA). HL-1 cells were maintained in Clay-
comb/DMEM media supplemented with 10% fetal bovine serum,
penicillin/streptomycin, and l-glutamine (Sigma-Aldrich). The
AtT20 pituitary cell line was obtained from Dr. Ken Mackie (Indi-
ana University) and grown in DMEM media with 10% horse
serum. Cells were platted on gelatin- (HL-1 cells) or poly l-lysine-
(AtT20 cells) coated glass coverslips (5,000 cells per coverslip;
patch clamp recording) and in black 96-well plates (Corning;
30,000 cells perwell; plate readermeasurements). Cells were stored
in an incubator at 37˚C (5% O2/95% CO2) and used on days 2–4
after plating.
PATCH CLAMP RECORDING OF GIRK CURRENTS
The patch clamp method (Hamill et al., 1981) was used to record
the whole-cell, GIRK currents using L/M EPC-7 (Adams and
List Associates) and Axopatch 200 (Axon Instruments) ampliﬁers.
Our procedures for measuring K+ channels have been described
(Walsh and Zhang, 2008; Walsh, 2010). Pipettes were made from
borosilicate glass capillaries (World Precision Instruments) and
had resistances of 1–2Mohm when ﬁlled with internal solution.
All experiments were conducted on isolated, non-coupled cells
at room temperature (22–24˚C). For the measurement of GIRK
currents, cells were placed in a normal buffer solution consisting
of; 132mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2, 5mM
dextrose, 5mM HEPES, pH 7.4 (with NaOH; 280mOsm). The
internal solution consisted of; 50mM KCl, 60mM K+–glutamate,
2mM MgCl2, 1mM CaCl2, 11mM EGTA, 3mM ATP, 0.1mM
GTP,10mMHEPES,pH 7.3 (withKOH; 280mOsm).Upon estab-
lishment of thewhole-cell conﬁguration, the cell was perfusedwith
a high K+ buffer solution containing; 107mM NaCl, 30mM KCl,
1mM CaCl2, 1mM MgCl2, 5mM dextrose, 5mM HEPES, pH 7.4.
Following the measurement of the cell background current, GIRK
channels were activated by the addition of the GPCR ligands car-
bachol (10μM; HL-1 cells) or somatostatin (200 nM; AtT20 cells)
using a rapid perfusion system. In each case the GIRK current was
deﬁned as the BaCl2-sensitive current (see Figure 1).
GIRK CHANNEL FLUORESCENT PLATE READER ASSAY
For measuring changes in the membrane potential, cells were
incubated for 1 h in normal buffer solution containing the
oxonol dye HLB 021-152 (5μM;AnaSpec) and ﬂuorescent signals
recorded using a Synergy2 microplate reader (Biotek) at 28˚C.
Test compounds were dissolved in DMSO at a stock concentra-
tion of 10mM, diluted to various concentrations and applied
to the cells for 5min prior to the ﬂuorescent measurements.
DMSO, up to 1% in normal buffer solution, had no adverse effects
on the cell response. Carbachol, somatostatin, or control solu-
tion (20μL) was added to each well (total volume= 220μL) at
time zero using the Synergy2 injector system. Data points were
collected at 10 s intervals over a 300-s sampling period at excita-
tion and emission wavelengths of 520 and 560 nm, respectively.
Z ′-factors (Zhang et al., 1999) were obtained by (1) comparing
the ﬂuorescent signal between wells injected with control solu-
tion and wells injected with the GPCR ligand and (2) comparing
the signal in wells injected with the GPCR ligand in the pres-
ence and absence of 2mM BaCl2. The Z ′-factor is deﬁned as:
Z ′ = 1− (3σP + 3σN)/|μP −μN |,whereμP andμN are themeans
of the positive control and negative control signals, and σP and
σN are the SD of the positive control and negative control sig-
nals, respectively (Zhang et al., 1999). Plates used for Z ′-factor
determination contained two rows each of positive and nega-
tive controls. Dose–response curves for selected compounds were
obtained and drug potencies determined by ﬁtting the data with
the curve: Max/(1+ ([drug]/IC50)k), where the IC50 is the con-
centration of the compound producing a 50% decrease in the
maximal GPCR response (Max) and k is the slope factor. Inter-
ference of the test compounds with the HLB 021-152 ﬂuores-
cence was determined in the absence of cells by adding various
concentrations of the compounds to buffer solution containing
the dye.
DRUGS AND CHEMICALS
Carbachol, somatostatin, and a Na+, K+ channel modulator kit
(catalog # LO2220), containing 68 compounds, were purchased
from Sigma-Aldrich Chemical Corp. Tertiapin-Q (synthetic for-
mulation) was obtained from Alomone Labs.
RESULTS
MEASUREMENT OF GIRK CURRENTS IN AtT20 CELLS
G protein-coupled inward rectiﬁer K+ channels are highly
expressed in the central and peripheral nervous system as well
as in endocrine tissue. The AtT20 cell line was originally derived
from a mouse pituitary tumor and expresses the somatostatin type
2 and 5 receptors (SSTR2 and SSTR5), voltage-gated Ca2+ chan-
nels, and GIRK1/GIRK2 channels (Mackie et al., 1995; Kuzhikan-
dathil et al., 1998). Although the AtT20 cells were ﬁrst thought
to be related to pituitary corticotrophs, recent evidence indi-
cates that these cells have functional and structural features
more in common with neuropeptide-secreting neurons. Thus, the
AtT20 cells provide a good model system for studying neuronal
signaling.
Figure 1 displays GIRK currents measured in the AtT20 cells
using the whole-cell arrangement of the patch clamp technique.
Cells were bathed in the high K+ buffer solution (30mM KCl)
and the internal (pipette) solution contained KCl/K+–glutamate
(140mM K+) with GTP. Application of somatostatin to the
recording chamber resulted in the activation of a Ba2+-sensitive,
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FIGURE 1 | Expression of GIRK channels in AtT20 cells. Left panel:
Currents were measured before (control) and after the addition of
somatostatin (200 nM) during voltage steps applied from the holding
potential of −40 to −60, −80, and −100mV. Addition of tertiapin (500 nM)
inhibited the current (bottom records). The solid lines represent zero
current. Top right panel: I/V relationship for the somatostatin activated
current (Som) displayed inward rectiﬁcation and a reversal potential of
−40mV. Current values were obtained by subtracting the currents by
records obtained in the presence of 1mM BaCl2. Each point represents
the mean±SE current (pA/pF) measured in three to ﬁve cells. Bottom
right panel: dose versus response curve for tertiapin-Q block of the AtT20
cell GIRK current. Each point represents the mean±SE inhibition obtained
from three to six experiments. The calculated IC50 value for tertiapin-Q
block was 60 nM.
inward rectifying current (Figure 1). The somatostatin–activated
current was blocked by addition of the GIRK channel blocker
tertiapin-Q (Jin and Lu, 1998; Figure 1). Tertiapin-Q blocked the
current with an IC50 of 60 nM (Figure 1). The reversal potential
(Erev) for the current (−40mV) was close to the calculated Nernst
equilibrium potential (EK; −39mV) for a K+-selective channel
under the conditions of the experiment. Thus, the inward rectify-
ing current versus voltage relationship, the tertiapin-Q-sensitivity,
and the K+ selectivity of the channel are all consistent with the
expression of GIRK channels in the AtT20 cells (Mackie et al.,
1995; Kuzhikandathil et al., 1998).
DEVELOPMENT OF A GIRK CHANNEL SCREENING ASSAY
Having conﬁrmed the presence of GIRK channels in theAtT20 cell
line, it was determined if these cells could be used for drug screen-
ing. The experimental design of the screening assay is outlined in
Figure 2. AtT20 cells were cultured in 96-well plates and loaded
with the ﬂuorescent membrane potential-sensitive dye HLB 021-
152 (AnaSpec). Membrane potential-sensitive dyes such as HLB
021-152 (D) distribute across the plasmamembranewhen cells are
in the rested state and reach equilibrium (Figure 2, top panel). The
dye molecules inside the cells become strongly ﬂuorescent upon
binding to intracellular proteins and other cytoplasmic compo-
nents. Treatment of the cellswith somatostatin (Som),which binds
FIGURE 2 | Development of a screening assay for identifying new
neuronal GIRK channel blockers.
to the somatostatin receptor (SSTR), activates the G inhibitory
protein (Gi) stimulating the GIRK channels to open (Figure 2,
bottom panel). The resulting efﬂux of K+ out of the cell (resting
potential of −50 to −60mV for AtT20 cells) causes the resting
membrane potential (Rm) to become more negative and the HLB
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021-152 molecules to redistribute to the outside of the cell. As a
result the cell ﬂuorescent signal is decreased.
The applicability of the GIRK channel ﬂuorescent assay for
drug discovery was evaluated in the experiments displayed in
Figure 3. Each ﬁgure plots the HLB 021-152 ﬂuorescence signal
measured over time in the 96-well plates using a microplate reader.
As predicted by the experimental model, addition of somato-
statin (200 nM) to the AtT20 cells caused a rapid, time-dependent
decrease in the HLB 021-152 ﬂuorescent signal (Figure 3). In con-
trast, addition of control solution produced only a small instan-
taneous rise in the ﬂuorescence (Figure 3). Comparison of peak
ﬂuorescent values in wells injected with control and somatostatin
solutions gave a Z ′-factor of 0.7. The Z ′-factor is used to quan-
tify the reliability of the assay (Zhang et al., 1999). Z ′-factors
in the range of 0.5–1.0 indicate that the quality of the assay is
excellent (Zhang et al., 1999). In order to quantify the GIRK
channel ﬂuorescent signal, the averaged control measurement,
obtained in each 96-well plate, was subtracted from the records
measured in the presence of somatostatin (Som – Con; Figure 3).
This control-subtracted ﬂuorescent signal (i.e., the somatostatin-
sensitive component) was subsequently obtained and analyzed
throughout the rest of the study. As shown in the top panel of
Figure 3, somatostatin activated the AtT20 cell GIRK channel in
a concentration dependent manner with a half-maximal effec-
tive concentration (EC50) of 4 nM. At a concentration of 200 nM
somatostatin caused a ﬂuorescent change (F /FO) of −0.088 (n = 6
wells). In comparison, addition of 10, 20, and 30mMKCl, to depo-
larize the cell membrane, produced ﬂuorescent changes of 0.058,
FIGURE 3 | Development of a GIRK channel blocker screening assay.Top
left panel: HLB 021-152 ﬂuorescent intensities obtained in AtT20 cells in the
presence or absence of somatostatin. The ratio of the ﬂuorescent intensity
(F /FO) was calculated by dividing the signal in the presence (F ) of
somatostatin (or control solution) by the baseline signal measured before (FO)
addition of somatostatin (or control solution). Each point represents the
mean±SE obtained in six to eight wells. Somatostatin was added at time
zero (↓). Top right panel: dose–response curve for the somatostatin-sensitive
ﬂuorescent signal (EC50 =4nM). Each point represents the mean±SE of six
measurements. Bottom left panel: changes in ﬂuorescent signal obtained
during injection of somatostatin, carbachol, and adenosine. Each point
represents the mean±SE obtained in six wells. Bottom right panel:
dose–response curve for the carbachol-sensitive ﬂuorescent signal
(EC50 =1μM). Each point represents the mean±SE of six measurements.
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0.13, and 0.15, respectively (n = 6 wells for each KCl concentra-
tion). It was also determined if stimulation of other Gi-coupled
GPCRs might activate the AtT20 cell GIRK channels. Application
of the muscarinic agonist carbachol resulted in a peak ﬂuores-
cent change of −0.037 (n = 6 wells; Figure 3, bottom panel). The
EC50 for carbachol activation of the channel was 1 μM (Figure 3,
bottompanel). In contrast, applicationof 10μMadenosine caused
no change in the ﬂuorescent signal.
IDENTIFICATION OF GIRK CHANNEL BLOCKERS IN AtT20 CELLS AND
CARDIAC HL-1 CELLS
It was next determined if the ﬂuorescent assay system could be
utilized for screening drugs that block GIRK channels. Inhibi-
tion of the GIRK channel should reduce somatostatin-mediated
changes in Rm by preventing K+ efﬂux from the cells. To pro-
vide proof of concept, the AtT20 cells were incubated for 5min
with either BaCl2 or tertiapin-Q prior to somatostatin addition.
As expected for a signal arising from GIRK channel activation,
treatment with BaCl2 (2mM) or tertiapin (500 nM) produced
a complete inhibition of the somatostatin-mediated ﬂuorescent
change (Figure 4). BaCl2 at concentrations of 0.5 and 1mM
reduced the ﬂuorescent change by 67± 4% and 92± 2% (n = 6
wells each), respectively.
We previously demonstrated that the GIRK channel ﬂuores-
cent assay could be utilized to study the pharmacology of the
GIRK1/GIRK4 channel in cardiac HL-1 cells (Walsh, 2010). The
HL-1 cells are an immortalized atrial cell line that displays an adult-
like cardiac genotype and contracts spontaneously in cell culture
(Whit et al., 2004). The cardiac GIRK channel is strongly blocked
by tertiapin (Nobles et al., 2010;Walsh, 2010). In Figure 4 the con-
centration versus inhibition response of tertiapin-Q on the GIRK
channel ﬂuorescent signal was compared in the AtT20 and HL-1
cells. Tertiapin-Q was nearly a 100-fold more potent in blocking
the GIRK channel in the HL-1 cells (IC50 = 1.4 nM) as compared
to the AtT20 cells (IC50 = 102 nM).
G protein-coupled inward rectiﬁer K+ channels are non-
speciﬁcally blocked by a number of drugs including anti-
arrhythmic agents, antipsychotic drugs, and antidepressants
(Kobayashi and Ikeda, 2006). As a ﬁrst step in expanding the lim-
ited pharmacology of the channel, the AtT20 and HL-1 cells were
screened against a small compound library of Na+ andK+ channel
modulators. Dose versus response curves were obtained for com-
pounds producing a 50%or greater inhibitionof theGPCR ligand-
induced signal when tested at a concentration of 1μM. Several
ion transporter inhibitors were identiﬁed as GIRK channel block-
ers. The Na+/H+ exchange inhibitors 5-(N,N -hexamethylene)-
amiloride (HMEA; Figure 5) and 5-(N -ethyl-N -isopropyl)-
amiloride (EIPA) blocked the GIRK channel with IC50s of 1μM in
both the AtT20 and HL-1 cells. In contrast, the parent compound
amiloride had no blocking effect when tested up to a concen-
tration of 10μM. The gastric H+/K+ transport inhibitor SCH-
28080 (2-methyl-8-(phenylmethoxy)imidazo[1,2-A]pyridine-3-
acetonitrile) potently reduced the GPCR-sensitive ﬂuorescent sig-
nal (IC50 = 0.2μMfor theAtT20 cells; IC50 = 0.3μMfor theHL-1
cells; Figure 5). However, no change in ﬂuorescence was measured
during treatment with the structurally related transport inhibitor
omeprazole (Figure 5).
FIGURE 4 | Block of GIRK channels by Ba2+ and tertiapin-Q.Top panel:
somatostatin-sensitive ﬂuorescent signal measured in AtT20 cells
pretreated for 5min with either 2mM BaCl2 or 500 nM tertiapin-Q. Each
point represents the mean±SE value obtained in six wells in one plate.
Bottom panel: dose versus response curve for tertiapin-Q block of the HL-1
cell (carbachol stimulation) or AtT20 cell (somatostatin stimulation) GIRK
ﬂuorescent signal. Each point represents the mean±SE inhibition obtained
from three to ﬁve experiments. Calculated IC50 values for tertiapin-Q block
were HL-1 cells=1.4 nM, AtT20 cells=102nM.
DISCUSSION
GIRK CHANNELS AS TARGETS FOR DRUG THERAPY
The goal of this study was to develop a screening assay for
identifying modulators of neuronal and cardiac GIRK channels.
For this purpose immortalized pituitary AtT20 and cardiac HL-
1 cells were cultured in 96-well plates, loaded with an oxonol
membrane potential-sensitive dye and analyzed with a ﬂuorescent
plate reader. Activation of the endogenous GPCRs in the cells,
through application of either somatostatin or carbachol, caused
a rapid, time-dependent decrease in the ﬂuorescent signal. This
change in the ﬂuorescent signal was blocked by treatment with
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FIGURE 5 | Block of GIRK channels by ion transporter inhibitors.Top
panel: somatostatin-sensitive ﬂuorescent signal measured in AtT20 cells
pretreated for 5min with drug vehicle solution (DMSO; Som) and either
1μM 5-(N,N -hexamethylene)-amiloride (HMEA) or 0.5μM SCH-28080.
Each point represents the mean±SE value obtained in six wells in one
plate. Bottom panel: dose versus response curve for drug block of the
somatostatin (AtT20 cells) or carbachol (HL-1 cells) signal. Each point
represents the mean±SE inhibition obtained from three to six
experiments. Calculated IC50 values were HMEA=1μM (AtT20 and HL-1
cells) and SCH-28020 (200 nM for AtT20 cells and 300 nM for HL-1 cells).
the GIRK channel blockers Ba2+ and tertiapin-Q. Thus, the GIRK
channel ﬂuorescent assay provides a fast, reliable, and inexpensive
procedure for identifying drugs that modulate GIRK channels.
G protein-coupled inward rectiﬁer K+ channel dysfunction
has been implicated in the patho-physiology of a number of
disorders including neuropathic pain, drug addiction, and cardiac
arrhythmias. Support for a role of GIRK channels in these disor-
ders has come primarily from studies with GIRK channel knock-
out mice. For example, GIRK channel knockout mice display a
reduced sensitivity to analgesics (Lusscher and Slesinger, 2010).
Dose–response curves for morphine-induced analgesia are shifted
to higher doses in both GIRK2 and GIRK1 subunit knockout
mice (Marker et al., 2004). Anti-nociceptive effects of ethanol,
oxotremorine (muscarinic agonist), nicotine, baclofen (GABA
agonist), clonidine (α2-adrenergic agonist), and WIN 55,212
(cannabinoid agonist) are also diminished in GIRK2 null mice
(Blednov et al., 2003; Mitrovic et al., 2003). Kovoor et al. (2001)
demonstrated that mice lacking the GIRK4 subunit are less sus-
ceptible to the development of atrial ﬁbrillation. This ﬁnding
is supported by recent studies indicating that the GIRK chan-
nel is constitutively activated in patients with atrial ﬁbrillation
(Dobrev et al., 2005). Therefore, although GIRK channels repre-
sent desirable targets for pharmacological therapy, drug develop-
ment has been hampered by the absence of a cell-based screening
system.
DEVELOPMENT OF A GIRK CHANNEL SCREENING ASSAY
The traditional approach to ion channel drug discovery has
involved the expression of recombinant channels in heterologous
cell lines such HEK-293 and CHO cells. However, these cells often
lack the relevant “physiological environment” that is present in
native tissues, and required for normal pharmacological responses
(Numann and Negulescu, 2001; Eglen and Reisine, 2010). Of
particular concern, the expression proﬁle of G proteins and ion
channels in HEK-293 cells differs from that found in muscle and
nerve (Numann and Negulescu, 2001; Eglen and Reisine, 2010).
Thus, recent interest has focused on the suitability of primary cells,
embryonic stem cells and clonal cell lines for drug discovery (Eglen
and Reisine, 2010).
In the present study, GIRK channels were screened using
the membrane potential-sensitive dye HLB 021-152. Membrane
potential-sensitive dyes have previously been used to study Kir
channels (Wolff et al., 2003). More recently, HEK-293 cells over-
expressing GIRK channels were successfully utilized to screen for
metabotropic glutamate receptor ligands using the thallium ﬂux
assay (Niswender et al., 2008). During the course of our experi-
ments we performed preliminary experiments using the thallium
ﬂux assay with the ﬂuorescent dye BTC–AM. Application of the
thalliumcontaining solution to theHL-1 andAtT20 cells produced
large non-linear background increases in the BTC ﬂuorescence.
This background signal was larger than the subsequent ﬂuores-
cent change produced by addition of the GPCR ligand. HL-1 cells
express the ether-à-go-go related gene (ERG) channel and other
K+ channels (Whit et al., 2004) that may allow thallium inﬂux
under basal conditions. Therefore, the thallium inﬂux assay is not
currently suitable for the AtT20 and HL-1 cell lines.
The AtT20 and Hl-1 cell lines represent ideal systems for GIRK
channel drug discovery. AtT20 cells express the GIRK1 and GIRK2
subunits as well as SSTR2 and SSTR5. HL-1 cells express the
GIRK1 andGIRK4 subunits alongwith themuscarinic type2 (M2)
receptor. Whole-cell acetylcholine-activated K+ currents (IK,Ach;
GIRK1/GIRK4 channel) are blocked by 100 nM tertiapin-Q in the
HL-1 cells (Nobles et al., 2010; Walsh, 2010). In the present study,
tertiapin-Q was nearly 100-fold more potent in blocking the HL-1
cell GIRK channel ﬂuorescent signal (Figure 4). Lu and colleagues
(Jin and Lu, 1998; Ramu et al., 2004) identiﬁed a short sequence
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of amino acids (approximately 10 amino acid residues), located
in the M1–M2 linker of Kir subunits, that determines the bind-
ing afﬁnity of tertiapin. Slight variances in this region greatly alter
the potency of tertiapin in blocking Kir channels (Ramu et al.,
2004). When expressed in Xenopus oocytes, homomeric GIRK1
and GIRK4 channel constructs are blocked by tertiapin-Q with
K d values of 20μM and 2 nM, respectively (Ramu et al., 2004).
Variances in this linker sequence may also account for the different
IC50s that were measured with tertiapin in the AtT20 and HL-1
cells.
Despite the different potencies of GIRK channel inhibition
produced by tertiapin-Q in the two cell lines, both cell types
displayed a similar sensitivity to the ionic transport inhibitors
HMEA, EIPA, and SCH-28080. GIRK channels are blocked
by a wide range of pharmacological agents including volatile
anesthetics (halothane, isoﬂurane, and enﬂurane), antipsychotic
drug (clozapine, pimozide, and haloperidol), and antidepressants
(imipramine, amitriptyline, and clomipramine; Kobayashi and
Ikeda, 2006; Lusscher and Slesinger, 2010). Furthermore, a num-
ber of anti-arrhythmic agents including amiodarone, ﬂecainide,
quinidine, and propafenone block GIRK channels in primary cul-
tures of atrial myocytes (Inomata et al., 1993; Watanabe et al.,
1996; Hashimoto et al., 2006) and in HL-1 cells (Walsh, 2010).
However, GIRK channel inhibition by these agents typically
requires drug concentrations in the micromolar range. Recently,
two benzopyran derivatives, NIP-151 and NTC-801, were demon-
strated to block GIRK1/GIRK4 channels at nanomolar concentra-
tions (Hashimoto et al., 2008; Machida et al., 2011). When tested
in a canine model of atrial ﬁbrillation, both compounds decreased
atrial excitability and converted AF to sinus rhythm (Hashimoto
et al., 2008; Machida et al., 2011). While the clinical efﬁcacy of
these agents is yet to be established, the results of these studies sup-
port the further development of new and selective GIRK channel
modulators.
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